Successful completion of a phase 1 randomized, double-blind placebo controlled, single ascending dose trial for the first in class angiotensin AT2-receptor agonist compound 21

U. Steckelings, L. Lindblad, A. Leisvuori, Z. Lovro, Petri Vainio, Johanna Gräns, Björn Dahlöf, Per Jansson, Thomas Unger, Pasi Korhonen, Mika Scheinin

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

OriginalsprogEngelsk
ArtikelnummerPP.02.17
TidsskriftJournal of Hypertension
Vol/bind35
Udgave nummere-supplement 2
Sider (fra-til)e105
Antal sider1
ISSN0263-6352
DOI
StatusUdgivet - sep. 2017
Begivenhed27th European Meeting on Hypertension and Cardiovascular Protection - MiCo Milano Congressi, Milan, Italien
Varighed: 16. jun. 201719. jun. 2017
http://www.esh2017.eu/

Konference

Konference27th European Meeting on Hypertension and Cardiovascular Protection
LokationMiCo Milano Congressi
LandItalien
ByMilan
Periode16/06/201719/06/2017
Internetadresse

Citationsformater

Steckelings, U., Lindblad, L., Leisvuori, A., Lovro, Z., Vainio, P., Gräns, J., Dahlöf, B., Jansson, P., Unger, T., Korhonen, P., & Scheinin, M. (2017). Successful completion of a phase 1 randomized, double-blind placebo controlled, single ascending dose trial for the first in class angiotensin AT2-receptor agonist compound 21. Journal of Hypertension, 35(e-supplement 2), e105. [PP.02.17]. https://doi.org/10.1097/01.hjh.0000523257.57873.95